2.9002 0.2 (7.41%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.72 | 1-year : | 4.05 |
Resists | First : | 3.18 | Second : | 3.47 |
Pivot price | 3.09 | |||
Supports | First : | 2.73 | Second : | 2.27 |
MAs | MA(5) : | 2.97 | MA(20) : | 3.09 |
MA(100) : | 3.33 | MA(250) : | 3.71 | |
MACD | MACD : | -0.2 | Signal : | -0.2 |
%K %D | K(14,3) : | 15.6 | D(3) : | 18.7 |
RSI | RSI(14): 40.3 | |||
52-week | High : | 5.38 | Low : | 1.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PROC ] has closed above bottom band by 10.7%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.91 - 2.93 | 2.93 - 2.94 |
Low: | 2.82 - 2.85 | 2.85 - 2.87 |
Close: | 2.86 - 2.9 | 2.9 - 2.94 |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Thu, 28 Mar 2024
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively - Simply Wall St
Thu, 28 Mar 2024
Procaps Group, S.A. Revenue Breakdown – NASDAQ:PROC – TradingView - TradingView
Tue, 26 Mar 2024
Procaps Group (NASDAQ:PROC) Trading Down 3.4% - Defense World
Mon, 04 Mar 2024
Procaps explores strategic alternatives to boost shareholder value - Investing.com
Mon, 04 Mar 2024
Procaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives - Business Wire
Mon, 12 Feb 2024
SNY: 5 Pharma Stocks to Watch With Bullish Momentum - StockNews.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 113 (M) |
Shares Float | 17 (M) |
Held by Insiders | 83 (%) |
Held by Institutions | 3.1 (%) |
Shares Short | 10 (K) |
Shares Short P.Month | 27 (K) |
EPS | 0.5 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.38 |
Profit Margin | 12.6 % |
Operating Margin | 11.1 % |
Return on Assets (ttm) | 6.2 % |
Return on Equity (ttm) | 373.7 % |
Qtrly Rev. Growth | 7.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 3.67 |
EBITDA (p.s.) | 0.5 |
Qtrly Earnings Growth | -63.8 % |
Operating Cash Flow | 63 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | 5.68 |
PEG Ratio | 0 |
Price to Book value | 7.43 |
Price to Sales | 0.79 |
Price to Cash Flow | 5.19 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |